Therapeutic Potential of Oncolytic Measles Virus: Promises and Challenges

被引：49

作者：

Galanis, E. ^{[1
,2
]}

机构：

[1] Mayo Clin, Dept Oncol, Rochester, MN 55905 USA

[2] Mayo Clin, Dept Mol Med, Rochester, MN USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2010年 / 88卷 / 05期

关键词：

SODIUM-IODIDE SYMPORTER; OVARIAN-CANCER; CARCINOEMBRYONIC ANTIGEN; GLIOBLASTOMA-MULTIFORME; CELLULAR RECEPTOR; PROSTATE-CANCER; VACCINE STRAIN; VIROTHERAPY; GLIOMAS; TUMOR;

D O I：

10.1038/clpt.2010.211

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Measles virus (MV) is a negative-strand RNA virus (paramyxovirus) with oncolytic properties. The significant preclinical activity of MV vaccine strains against a variety of tumor models, their potent bystander effect, their selectivity against tumor cells, and their ability to retain their oncolytic properties when engineered and retargeted makes them a promising oncolytic platform. In this article, we review potential applications and challenges associated with use of MV strains as cancer therapeutics.

引用

页码：620 / 625

页数：6

共 52 条

[1]

ALLEN C, 2007, MOL THER S1, V15, pS22

[2] Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity [J].

Allen, Cory ;

Paraskevakou, Georgia ;

Iankov, Ianko ;

Giannini, Caterina ;

Schroeder, Mark ;

Sarkaria, Jann ;

Schroeder, Mark ;

Puri, Raj K. ;

Russell, Stephen J. ;

Galanis, Evanthia .

MOLECULAR THERAPY, 2008, 16 (09) :1556-1564

[3]

Allen C, 2008, EXPERT OPIN BIOL TH, V8, P213, DOI [10.1517/14712598.8.2.213, 10.1517/14712598.8.2.213 ]

[4] Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity [J].

Allen, Cory ;

Vongpunsawad, Sompong ;

Nakamura, Takafumi ;

James, C. David ;

Schroeder, Mark ;

Cattaneo, Roberto ;

Giannini, Caterina ;

Krempski, James ;

Peng, Kah-Whye ;

Goble, Jenny M. ;

Uhm, Joon H. ;

Russell, Stephen J. ;

Galanis, Evanthia .

CANCER RESEARCH, 2006, 66 (24) :11840-11850

[5] High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus [J].

Anderson, BD ;

Nakamura, T ;

Russell, SJ ;

Peng, KW .

CANCER RESEARCH, 2004, 64 (14) :4919-4926

[6] Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma [J].

Blechacz, Boris ;

Splinter, Patrick L. ;

Greiner, Suzanne ;

Myers, Rae ;

Peng, Kah-Whye ;

Federspiel, Mark J. ;

Russell, Stephen J. ;

LaRusso, Nicholas F. .

HEPATOLOGY, 2006, 44 (06) :1465-1477

[7]

BLUMING AZ, 1971, LANCET, V2, P105

[8] SUCCESSES AND FAILURES IN MEASLES CONTROL [J].

CUTTS, FT ;

MARKOWITZ, LE .

JOURNAL OF INFECTIOUS DISEASES, 1994, 170 :S32-S41

[9] Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter [J].

Dingli, D ;

Peng, KW ;

Harvey, ME ;

Greipp, PR ;

O'Connor, MK ;

Cattaneo, R ;

Morris, JC ;

Russell, SJ .

BLOOD, 2004, 103 (05) :1641-1646

[10] THE HUMAN CD46 MOLECULE IS A RECEPTOR FOR MEASLES-VIRUS (EDMONSTON STRAIN) [J].

DORIG, RE ;

MARCIL, A ;

CHOPRA, A ;

RICHARDSON, CD .

CELL, 1993, 75 (02) :295-305

← 1 2 3 4 5 6 →